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Drug or tool, design or
serendipity?
Christophe L.M.J. Verlinde1 and Bauke W. Dijkstra2
Iterative protein structure-based ligand design has led to a 'selective' inhibitor of human non-
pancreatic secretory phospholipase A2 which provides anew tool for probing metabolic pathways
and may lead to a useful drug.
Fig. 1 Traditional view of the inflammation cascade. Cytokines, such as interleukin-l or tumour
necrosis factor, induce synthesis and secretion of PLA,. Thissynthesis can be prevented by the administration
of glucocorticosteroids. PLA, hydrolyzes membrane phospholipids liberating arachidonic acid. This step
can be blocked by the new inhibitor LY311727, designed by Schevitz et aU Arachidonic acid can be
metabolized by cyclo-oxygenases, a step that can be inhibited by aspirin, or by 5-lipoxygenases. This
metabolism gives rise to potent mediators of inflammation, such as prostaglandins, thromboxanes and
leukotrienes.
Blocking human non-pancreatic
secretory phospholipase A, (hnps-
PLA,) may open new doors to the 4.3
billion dollars world market' of non-
steroidal anti-inflammatory drugs
(NSAIDs). At least this has been the
hope of many pharmaceutical com-
panies for more than twenty years.
Thus far, their scramble for this po-
tentially massive financial reward has
been in vain'. However, in this issue
of Nature Structural Biology Schevitz
et al.3, researchers at Eli Lilly, report
that they have crafted a potent in-
hibitor of hnps-PLA, that displays
1500-fold selectivity when assayed
against pancreatic PLA,. They have
based their strategy on a clever
screening assay and a process of it-
erative protein structure-based
ligand design. An important lesson
of their successful design is that it is
rooted in a 'common sense' approach
rather than elaborate computational
methods. It remains to be seen, how-
ever, whether the new inhibitor will
ever make it onto the market as a
drug. That will depend on pertinent
pharmacodynamic properties. Per-
haps the biggest significance of the
inhibitor is that it will be a new tool
for unraveling the pharmacological
importance of the biochemical path-
ways on which PLA, operates. The
big question remains, though: can
the successful rational approach fol-
lowed by the Eli Lilly researchers be
applied to other proteins as well, or
does the process of selective design
still involve some considerable
amount of luck?
PLA2 pharmacology
Phospholipase A, enzymes hydrolyze
the sn-2 ester bond of membrane
phospholipids, liberating free fatty
acids and Iysophospholipids. Phar-
macological interest in this reaction
stems from the belief that PLA, -cata-
lyzed release of arachidonic acid is
the rate-limiting step in the biosyn-
thesis of potent mediators of inflam-
mation and allergy, such as prostag-
landins, thromboxanes and
leukotrienes' (Fig. 1). Control of
PLA, activity should translate into
diverse medical applications, such as
relief for patients with rheumatoid
arthritis, and increased survival
chances in cases of endotoxic shock
or pancreatitis4.
Unfortunately, the existence of
multiple forms of PLA, complicates
the understanding of the cellular
mechanisms of arachidonic acid
production. In humans there are
two 14,000 M, secretory PLA,s, one
produced in the pancreas and the
other found in inflammatory cells
and exudates, this latter enzyme be-
ing referred to as hnps-PLA,. Both
enzymes are not specific for arachi-
donic acid-containing phospholip-
ids, and their activity is not regulated
by allosteric effectors. In contrast,
there is a 87,000 M, cytosolic PLA,
with a clear preference for arachi-
donic acid phospholipidss, of which
the activity is regulated by phospho-
rylation'. Because there are no in-
hibitors known that selectively block
only one of the PLA,s the implica-
tion of hnps-PLA, in inflammation
is based on circumstantial evidence
rather than facts6. The selective in-
hibitor designed by Schevitz et al.
may resolve this issue.
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Lead discovery
The first step in the precarious un-
dertaking of drug design is to find a
good lead molecule. In principle, a
lead is a molecule with micromolar
affinity, or activity, that lends itself
to easy chemical modification. Cur-
rent approaches to find leads are
based on screening of many com-
pounds, usually of the order of
100,000. If the three-dimensional
structure of the target protein is
known computer-based methods
can reduce the screening efforts to
about 100 compounds in favourable
cases7~
The researchers at Eli Lilly es-
chewed computers and went for the
traditional screening method. In two
and a half years they screened about
90,000 compounds against hnps-
PLA2. Many of the compounds were
evaluated in three different assays: a
'quick and dirty' Eschericha coli as-
say, a robust chromogenic assay, and
a response test in lung tissue. Great
care was taken to evaluate PLA2 in-
hibition in an appropriate manner.
Because PLA2 operates at a lipid/wa-
ter interface this is far from trivial,
but the relevant protocols have been
established8. The tissue assay was
crucial to verify that the inhibitors
would not be active in vivo for the
wrong reasons, namely by inhibiting
cydo-oxygenase, an enzyme down-
stream in the inflammation cascade
(Fig. 1). To their surprise, Schevitz
et al. found a molecule that is very
similar to indomethacin, a known
NSAID.
Indomethacin is a strong inhibi-
tor of cydo-oxygenase, but had been
shown to weakly block hnps-PLA2 as
early as 19789. It is noteworthy that
indomethacin was discovered in a
serotonin antagonist research pro-
gram by researchers at Merck in
19631°. This program had been
started in 1957 because of the incor-
rect belief that serotonin was a me-
diator of inflammation11. This illus-
trates that it is not uncommon for
drugs to be discovered for the wrong
reasons, and that good leads for cur-
rent drug-design programs may
have been around for decades.
Fig. 2 Hnps-PLA2 and porcine pancreatic PLA2. Ribbon diagram of hnsp-PLA2
(red; Nand C termini are indicated) with side chains of residues that may explain the
discrimination between hnsp-PLA2(black side chains) and porcine pancreatic secretory
PLA2(green side chains) by LY311727 (molecule in the centre of the figure). The Tyr
69 side chain of the porcine enzyme has to move out of the way in order to
accommodate the inhibitor. This postulated conformation (yellow) has in fact been
observed for a mutant of the porcine enzyme in the presence of an amide substrate
analogue'6. Figure made with the program GRASP23
Lead optimization
During lead optimization several
desirable properties of a lead are
improved. The first goal is to in-
crease the affinity of the molecule
because this should guarantee a high
degree of selectivity, an adage that is
described in an old folktale: only
Cinderella's foot is perfectly comple-
mentary to the slipper she lost at the
ball. Just as a person will avoid an
ill-fitting shoe, an enzyme that com-
petes with hnps-PLA2 for inhibitor
binding will be a poor competitor if
the fit of the ligand is not perfect.
Traditional lead optimization re-
lies on synthesis of large series of de-
rivatives in the hope that a few of
them will have increased potency.
Rather than take this shot-gun ap-
proach, the Eli Lilly researchers de-
termined the crystal structure of the
complex between hnps-PLA2 and
their lead molecule. This led to two
surprises. First, the carboxylic-acid
function of the lead makes a direct
hydrogen bond to the carboxylate
moiety of Asp 49. Docking methods
would never have found this bind-
ing mode because both chemical
groups would normally be assumed
to be negatively charged. Second,
there is no Ca2+bound to hnps- PLA2
in this complex despite the fact that
the enzyme has a Km of 1.5 mM for
Ca2+ (ref. 12) and there was 10 mM
Ca2+ present in the medium. Com-
pared to the unliganded structure13,14
several conformational changes of
the protein to accommodate the
ligand are observed: the side chain
of His 6 swings out of the active site,
and Leu 2 and Lys 69 create space for
the 5- methoxy moiety of the ligand.
This dearly illustrates the necessity
of solving crystal structures of en-
zyme-inhibitor complexes as our
poor understanding of protein flex-
ibility prevents us from adequately
predicting ligand binding modes.
In the process of lead optimiza-
tion Schevitz et al. again made no
use of modern computational meth-
ods1s where the addition of thou-
sands of substituents to a lead is
evaluated for complementarity to the
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Table 1 Residues in contact' with LY311727
Residue No. hnps-PLA, pps-PLA, ' hps-PLA,3 Note
2 Leu Leu Val
5 Phe * 4 *
6 His Arg Arg swings out for inhibitor binding
9 lie * *
18 Ala Pro Pro
22 Tyr Phe Tyr backbone and CB atoms in contact
23 Gly Asn Asn
28 His Tyr Tyr backbone atoms in contact
29 Cys * *
30 Gly * *
45 Cys * *
48 His * *
49 Asp * *
52 Tyr * *
69 Lys Tyr Tyr
106 Phe * *
'Contact is defined as the sum of the van der Waals radii plus a tolerance of 10 Å;'
pps = porcine pancreatic secretory; 3hps = human pancreatic secretory; 4* means
that the residue is identical to the one in hnps-PLA,.
target enzyme. As before, they went
for a 'common sense' approach by
mimicking what was already known
about PLA, biochemistry. The Eli
Lilly researchers successfully pasted
onto their lead the two Ca'+ ligand
moieties of the potent non-selective
PLA, inhibitor (R)-2-dodecanoyl-
amino-l-hexanol-phosphoglycol,
for which the binding mode is
known16. Again, determining the
crystal structure of the complex with
the new ligand proved to be ex-
tremely informative. For example,
the 5-methoxy group of the new
inhbitor moved by 5 A compared to
its position in the complex of PLA2
with the original lead molecule. Such
major shifts of lead molecules have
now been seen several times by pro-
tein crystallographers: similar
ligands do not necessarily bind in
similar modes17,18.
After four rounds of structure-
based ligand design, with a turn-
around time per cycle of about three
weeks, Schevitz et al. obtained a
ligand, LY311727, which was 750
times more potent than their lead
against hnps-PLA2.
Selectivity
The Eli Lilly researchers announce that
their inhibitor is 1,500 times more
potent against hnps-PLA, than against
porcine pancreatic PLA2. However,
nowhere in their strategy did they take
the structure of the pancreatic enzyme
into account. The obtained selectivity
seems to be only a consequence of the
aim for maximal potency and, there-
fore, maximal complementarity to
hnps-PLA,. Can we understand the
origin of this selectivity?
We docked the selective Eli Lilly
inhibitor LY31172 7 in the structure
of hnps-PLA" as observed in the
presence of a transition state ana-
logue14, by means of the program
BIOGRAF19. Next, we verified the
docking mode by careful visual
comparison with the stereo figure in
the paper by Schevitz et al (the mod-
elling step was necessary since the
coordinates of the Eli Lilly PLA,
complexes are on hold). Subse-
quently, the structure of a mutant
porcine pancreatic PLA2 as observed
in the presence of an amide substrate
analogue16 and wild-type porcine
PLA, in the absence of a ligand'0 were
superimposed on the hnps-PLA2
structure (Fig. 2). Comparison of
residues whose side chains contact
the inhibitor does not give a clear-
cut reason why the inhibitor should
be selective. The Ala 18 residue con-
tacts the benzyl system of LY31172 7.
The equivalent Pro residue of the
porcine enzyme is about 1A further
away, which may lead to poor pack-
ing of the benzyl substituent in the
molecular complex. Val 31 of hnsp-
PLA, makes hydrophobic interac-
tions with the ring system of the in-
hibitor. The equivalent Leu of por-
cine PLA2 would bump into this ring
system and should therefore rotate
away to avoid the clash. This would
amount to exposing part of the Leu
side chain and part of the ring sys-
tem of LY311727 to solvent, for
which an en tropic energy penalty
would have to be paid. Tyr 69 of por-
cine PLA2 provides the same con-
tacts as Lys 69 of hnps-PLA, in the
complex structures; at least, in the
'swung out' conformation as ob-
served in the presence of the amide
substrate analogue16. In the absence
of a ligand the Tyr side chain is
'swung in"0 and would preclude
binding. Since such a conforma-
tional change is vital for the func-
tioning of the enzyme it seems likely
that the associated energetic cost is
minimal. In conclusion, one has to
assume that the selectivity factor of
1,500 would have to be ascribed to
the differences at residues 18 and 31.
A second question that arises is
whether selectivity against the por-
cine pancreatic enzyme is relevant,
because a drug will have to deal with
the human pancreatic enzyme. Di-
rect testing against this enzyme is a
problem since the enzyme is not
readily available. A sequence align-
ment (Table 1) demonstrates that of
the 16 residues that presumably con-
tact the inhibitor one is different
between the porcine and human
pancreatic enzyme: porcine Leu 2 is
a Val in the human PLA2. Leu 2
makes hydrophobic interactions
with both the benzyl system and the
indole ring of the inhibitor. Obvi-
ously the smaller Val side chain will
make less extensive interactions.
Therefore, LY311727 should be even
more selective when tested against
human pancreatic PLA2.
The road to drug
How far away are the researchers at
Eli Lilly from an effective drug? Ac-
cording to Connolly and Robinson21
a hnps-PLA2 inhibitor should:
♦possess PLA2 specificity in vitro
and the IC50 should be better than
1 µM for enzyme and cellular assays;
♦exhibit in vivo anti-inflamma-
tory activity in animals sensitive to
NSAIDs, 5-lipoxygenase inhibitors
or platelet activiating factor (PAF)
antagonists;
♦be orally active with a therapeu-
tically effective dose in 50 % of the sub-
jects (ED50) smaller than 10 mgkg1;
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♦reduce multiple lipid mediators in
inflammatory exudates or tissues.
Only the first condition has been
demonstrated for LY311727 at
present, while there are indications
that the last condition is met from
lung strips assay'. The second and
third factors are strongly related to
the pharmacodynamics issues of ab-
sorption, distribution in the body,
metabolism and excretion. For ex-
ample, most of the peptidomimetics
developed by protein structure-
based design as HIV protease inhibi-
tors have extremely short serum
half-lives, less than an hour, and are
therefore of no therapeutic use22.
Even if there are no problems with
the pharmacodynamic properties of
a molecule one still does not have a
drug. Many promising molecules do
not survive the stringent criteria of
extensive toxicological testing.
Genesis of a tool
From the work by Schevitz et al. it is
clear how valuable a cyclical process
of structure-based design is for lead
optimization. It also highlights the
current problems of purely compu-
tational design: a poor understanding
of the energetics of molecular inter-
actions, difficulties to handle confor-
mational flexibility,and a lack of pre-
dictive tools for pharmacodynamics
and toxicology15.Without any doubt
LY311727 is an extremely useful tool
to study the role of secretoryphospho-
lipases in the inflammation process.
It's future as a route to an effective
drug is less clear.
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